Skip to main content
Date Issued
Submitting OIG
Department of Health & Human Services OIG
Agencies Reviewed/Investigated
Department of Health & Human Services
Report Number
OEI-01-21-00400
Report Type
Inspection / Evaluation
Agency Wide
Yes
Number of Recommendations
2
Questioned Costs
$0
Funds for Better Use
$0
Report updated under NDAA 5274
No
External Link
https://oig.hhs.gov/documents/evaluation/10160/OEI-01-21-00400.pdf

Open Recommendations

This report has 2 open recommendations.
Recommendation Number Significant Recommendation Recommended Questioned Costs Recommended Funds for Better Use Additional Details
25-E-01-010.01 No $0 $0

FDA should define specific factors that would require FDA's accelerated approval council to advise on certain drug applications.

25-E-01-010.02 No $0 $0

FDA should take steps to ensure appropriate documentation of meetings with sponsors in drug approval administrative files.

Department of Health & Human Services OIG

United States